Literature DB >> 11161384

The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas.

S Maula1, R L Huuhtanen, C P Blomqvist, T A Wiklund, P Laurila, R Ristamäki.   

Abstract

In many malignant diseases the expression levels of CD44 and its splice variant v6 (CD44v6) have been associated with the prognosis. The purpose of this study was to investigate the clinical significance of CD44 in adult soft tissue sarcomas (STS). 133 STS patients with a limb or superficial trunk tumour treated at the Helsinki University Central Hospital in 1987-1993 with a median follow-up time of 68 months were included in this study. The expression of CD44 and CD44v6 was determined immunohistochemically on paraffin-embedded tumour samples. 95% of the tumours expressed CD44 and CD44v6 was detected in 57%. Strong CD44 expression was associated with low grade (P = 0.04) and small tumour size (P = 0.02). In diploid tumours the CD44 expression was correlated with low S-phase fraction (P = 0.001). High expression of both, CD44 in general as well as that of CD44v6, predicted a higher risk for local recurrence (CD44: P = 0.01 and CD44v6: P = 0.05). Low CD44v6 content of the primary tumour correlated with poor survival (P = 0.02). Determining the expression of CD44 or CD44v6 in a primary STS could be a valuable tool for selecting the group of patients who might benefit from intensified local tumour treatment. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11161384      PMCID: PMC2363706          DOI: 10.1054/bjoc.2000.1590

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  37 in total

1.  Homotypic cell aggregation induced by anti-CD44(Pgp-1) monoclonal antibodies and related to CD44(Pgp-1) expression.

Authors:  P C Belitsos; J E Hildreth; J T August
Journal:  J Immunol       Date:  1990-03-01       Impact factor: 5.422

2.  Binding of malignant lymphoid cells to the white matter of the human central nervous system: role of different CD44 isoforms, beta 1, beta 2 and beta 7 integrins, and L-selectin.

Authors:  R Aho; H Kalimo; M Salmi; D Smith; S Jalkanen
Journal:  J Neuropathol Exp Neurol       Date:  1997-05       Impact factor: 3.685

3.  Localized extremity soft tissue sarcoma: an analysis of factors affecting survival.

Authors:  C Collin; J Godbold; S Hajdu; M Brennan
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

4.  Survival in soft tissue sarcoma. Prognostic variables identified by multivariate analysis.

Authors:  B Rööser; R Attewell; N O Berg; A Rydholm
Journal:  Acta Orthop Scand       Date:  1987-10

5.  Prognosis in high-grade soft tissue sarcomas. The Scandinavian Sarcoma Group experience in a randomized adjuvant chemotherapy trial.

Authors:  T A Alvegård; N O Berg; J Ranstam; A Rydholm; B Rööser
Journal:  Acta Orthop Scand       Date:  1989-10

6.  Antibodies against the CD44 p80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation.

Authors:  S M Denning; P T Le; K H Singer; B F Haynes
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

7.  Redistribution of a major cell surface glycoprotein during cell movement.

Authors:  K Jacobson; D O'Dell; B Holifield; T L Murphy; J T August
Journal:  J Cell Biol       Date:  1984-11       Impact factor: 10.539

8.  Monoclonal antibodies to human lymphocyte homing receptors define a novel class of adhesion molecules on diverse cell types.

Authors:  L J Picker; M Nakache; E C Butcher
Journal:  J Cell Biol       Date:  1989-08       Impact factor: 10.539

9.  Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures.

Authors:  K Miyake; K L Medina; S Hayashi; S Ono; T Hamaoka; P W Kincade
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

10.  Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells.

Authors:  S Jalkanen; R F Bargatze; J de los Toyos; E C Butcher
Journal:  J Cell Biol       Date:  1987-08       Impact factor: 10.539

View more
  5 in total

1.  Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67.

Authors:  Jacob Engellau; Annette Persson; Pär-Ola Bendahl; Måns Akerman; Henryk A Domanski; Bodil Bjerkehagen; Peer Lilleng; Johan Weide; Anders Rydholm; Thor A Alvegård; Mef Nilbert
Journal:  Virchows Arch       Date:  2004-08-07       Impact factor: 4.064

2.  Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma.

Authors:  Hiroyuki Tsuchie; Makoto Emori; Naohisa Miyakoshi; Hiroyuki Nagasawa; Kyoji Okada; Hiroshi Nanjyo; Yasutaka Murahashi; Emi Mizushima; Junya Shimizu; Toshihiko Yamashita; Yoichi Shimada
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

3.  Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study.

Authors:  Christiane Matuschek; Marcus Lehnhardt; Peter Arne Gerber; Christopher Poremba; Jackson Hamilton; Guido Lammering; Klaus Orth; Wilfried Budach; Hans Bojar; Edwin Bölke; Matthias Peiper
Journal:  Eur J Med Res       Date:  2014-02-03       Impact factor: 2.175

Review 4.  Cancer Stem Cell Hierarchy in Glioblastoma Multiforme.

Authors:  Amy Bradshaw; Agadha Wickremsekera; Swee T Tan; Lifeng Peng; Paul F Davis; Tinte Itinteang
Journal:  Front Surg       Date:  2016-04-15

5.  CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.

Authors:  V Leuci; G M Casucci; G Grignani; R Rotolo; U Rossotti; E Vigna; L Gammaitoni; G Mesiano; E Fiorino; C Donini; A Pisacane; L D Ambrosio; Y Pignochino; M Aglietta; A Bondanza; D Sangiolo
Journal:  Oncoimmunology       Date:  2018-02-15       Impact factor: 8.110

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.